O

OrbiMed Portfolio holdings

AUM $5.4B Turnover 40.13%
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+34.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.26B
AUM Growth
+$251M
Cap. Flow
-$193M
Cap. Flow %
-4.53%
Top 10 Hldgs %
40.49%
Holding
127
New
24
Increased
16
Reduced
24
Closed
18
Avg Time Held Equity + Options
2.2 years
Top 10 Avg Time Held Equity + Options
1.9 years
Top 20 Avg Time Held Equity + Options
1.8 years
Avg Time Held Equity only
2.4 years
Top 10 Avg Time Held Equity only
1.9 years
Top 20 Avg Time Held Equity only
1.8 years

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$52.4M
2
CI icon
Cigna
CI
+$48.2M
3
UTHR icon
United Therapeutics
UTHR
+$38.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$29.4M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$28.9M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$105M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$93.6M
3
THC icon
Tenet Healthcare
THC
+$81.8M
4
BSX icon
Boston Scientific
BSX
+$39.8M
5
CYTK icon
Cytokinetics
CYTK
+$35.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.63%
2 Miscellaneous 2.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TMO icon
51
Thermo Fisher Scientific
TMO
$249B
$22.6M 0.53%
46,500
– –
2013 Q2
49 quarters
RYTM icon
52
Rhythm Pharmaceuticals
RYTM
$5.97B
$21.7M 0.51%
215,152
-33,360
-13% -$3.1M
2023 Q3
8 quarters
ABT icon
53
CALL
Abbott
ABT
$178B
$20.1M 0.47%
+150,000
New +$19.7M
2025 Q3
0 quarters
BSX icon
54
CALL
Boston Scientific
BSX
$62.3B
$19.5M 0.46%
+200,000
New +$20.7M
2025 Q3
0 quarters
KRYS icon
55
Krystal Biotech
KRYS
$9.79B
$18.1M 0.43%
102,745
+93,545
+1,017% +$14M
2023 Q4
7 quarters
FBRX icon
56
DELISTED
Forte Biosciences
FBRX
$18M 0.42%
1,196,955
– –
2024 Q4
3 quarters
AVTX icon
57
Avalo Therapeutics
AVTX
$635M
$17.1M 0.4%
1,349,300
+382,300
+40% +$3.29M
2024 Q3
4 quarters
XENE icon
58
Xenon Pharmaceuticals
XENE
$3.28B
$16.8M 0.4%
419,600
-528,277
-56% -$18.6M
2016 Q3
36 quarters
CARL icon
59
Carlsmed
CARL
$378M
$16.8M 0.39%
+1,252,600
New +$17.1M
2025 Q3
0 quarters
KROS icon
60
Keros Therapeutics
KROS
$219M
$16.1M 0.38%
1,018,734
– –
2020 Q2
21 quarters
PRLD icon
61
Prelude Therapeutics
PRLD
$258M
$15.7M 0.37%
10,909,256
– –
2020 Q3
20 quarters
STTK icon
62
Shattuck Labs
STTK
$535M
$15.1M 0.35%
+6,306,127
New +$7.72M
2025 Q3
0 quarters
CRBP icon
63
Corbus Pharmaceuticals
CRBP
$85.3M
$14.8M 0.35%
1,172,287
– –
2024 Q3
4 quarters
URGN icon
64
UroGen Pharma
URGN
$1.79B
$13.7M 0.32%
689,000
+210,600
+44% +$3.78M
2025 Q2
1 quarter
VIR icon
65
Vir Biotechnology
VIR
$1.76B
$13.6M 0.32%
2,380,715
– –
2023 Q4
7 quarters
FOLD icon
66
DELISTED
Amicus Therapeutics
FOLD
$13M 0.3%
1,645,400
-640,000
-28% -$4.55M
2023 Q4
7 quarters
PFE icon
67
CALL
Pfizer
PFE
$166B
$12.7M 0.3%
+500,000
New +$12.3M
2025 Q3
0 quarters
TARS icon
68
Tarsus Pharmaceuticals
TARS
$3.38B
$11.8M 0.28%
197,900
– –
2025 Q1
2 quarters
CCCC icon
69
C4 Therapeutics
CCCC
$321M
$11.6M 0.27%
5,235,146
-1,595,154
-23% -$3.83M
2024 Q2
5 quarters
AZN icon
70
CALL
AstraZeneca
AZN
$251B
$11.5M 0.27%
75,000
+25,000
+50% +$3.78M
2025 Q2
1 quarter
CGEM icon
71
Cullinan Oncology
CGEM
$878M
$11.4M 0.27%
1,923,855
– –
2021 Q1
18 quarters
VTGN icon
72
VistaGen Therapeutics
VTGN
$9.17M
$10.9M 0.26%
+3,060,000
New +$9.14M
2025 Q3
0 quarters
AMLX icon
73
Amylyx Pharmaceuticals
AMLX
$3.39B
$10.2M 0.24%
750,600
+437,400
+140% +$4.12M
2024 Q4
3 quarters
ACET icon
74
Adicet Bio
ACET
$45.8M
$9.27M 0.22%
715,446
– –
2018 Q1
30 quarters
PMVP icon
75
PMV Pharmaceuticals
PMVP
$66.3M
$8.37M 0.2%
5,975,291
-500,000
-8% -$692K
2020 Q3
20 quarters
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2025 Portfolio in Review

As of Q3 2025, OrbiMed held 127 positions worth $4.26B, up 6.3% from $4B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $193M in Q3 2025, closing 18 positions and reducing 24 holdings. Its most notable exit was UnitedHealth, an estimated $105M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Danaher worth $52.2M.

  • OrbiMed's largest Q3 2025 buy was Danaher: 263,100 shares worth $52.2M.
  • OrbiMed added most to Ascendis Pharma A/S in Q3 2025, an estimated $29.4M increase.
  • OrbiMed's biggest Q3 2025 reduction was Boston Scientific, cutting an estimated $39.8M.
  • OrbiMed fully exited UnitedHealth in Q3 2025, selling an estimated $105M.
  • OrbiMed's ten largest holdings make up 40% of its $4.26B portfolio in Q3 2025.
  • OrbiMed opened 24 new positions and closed 18 in Q3 2025.
  • OrbiMed's portfolio value rose 6.3% quarter-over-quarter to $4.26B.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.